Gilead Sciences (GILD) EBIT (QoQ) (2009 - 2026)
Gilead Sciences (GILD) EBIT (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.87 Bn | 632.12 Bn | 17.26 Bn |
| 2 | AbbVie | 470.09 Bn | 463.52 Bn | 12.70 Bn |
| 3 | Merck | 375.69 Bn | 368.55 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.40 Bn | 295.71 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.51 Bn | 252.61 Bn | 12.86 Bn |
| 6 | Amgen | 236.27 Bn | 222.28 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.86 Bn | 178.68 Bn | 6.22 Bn |
| 8 | Pfizer | 159.32 Bn | 147.62 Bn | 10.94 Bn |
| 9 | Gsk | 106.16 Bn | 101.99 Bn | 8.24 Bn |
| 10 | Sanofi | 55.12 Bn | 47.74 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -501.93% |
| Mar 31, 2026 | 30.34% |
| Dec 31, 2025 | -40.37% |
| Sep 30, 2025 | 34.48% |
| Jun 30, 2025 | 10.59% |
| Mar 31, 2025 | -8.77% |
| Dec 31, 2024 | 176.13% |
| Sep 30, 2024 | -66.41% |
| Jun 30, 2024 | 161.18% |
| Mar 31, 2024 | -368.11% |
| Dec 31, 2023 | -38.54% |
| Sep 30, 2023 | 57.54% |
| Jun 30, 2023 | -2.35% |
| Mar 31, 2023 | -24.79% |
| Dec 31, 2022 | -20.09% |
| Sep 30, 2022 | 39.82% |
| Jun 30, 2022 | 929.95% |
| Mar 31, 2022 | -79.04% |
| Dec 31, 2021 | -75.53% |
| Sep 30, 2021 | 71.06% |